Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis

Journal of Dermatological Science

Volumn 31, Issue 2, 2003, Pages 161-164

  Umemoto, Naoka ^a   Kakurai, Maki ^a   Okazaki, Hitoaki ^a   Kiyosawa, Tomoharu ^a   Demitsu, Toshio ^a   Nakagawa, Hidemi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; ELISA; VIP

Indexed keywords

IMMUNOGLOBULIN E; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CELL COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEASUREMENT; PATHOGENESIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0037379611     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(03)00004-5     Document Type: Article

References (14)

1. Scholzen T., Armstrong C.A., Bunnett N.W., Luger T.A., Olerud J.E., Ansel J.C. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp. Dermatol. 7:1998;81-96.
2. Rossi R., Johansson O. Cutaneous innervation and the role of neuronal peptides in cutaneous inflammation: a minireview. Eur. J. Dermatol. 8:1998;299-306.
3. Al'abadie M.S.K., Senior H.J., Bleehen S.S., Gawkrodger D.J. Neuropeptides and general neuronal marker in psoriasis - an immunohistochemical study. Clin. Exp. Dermatol. 20:1995;384-389.
4. Anand P., Springall D.R., Blank M.A., Sellu D., Polak J.M., Bloom S.R. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. Br. J. Dermatol. 124:1991;547-549.
5. Giannetti A., Fantini F., Cimitan A., Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Dermatol. Venereol. Stockh. Suppl. 176:1992;90-92.
6. Pincelli C., Fantini F., Romualdi P., Lesa G., Giannetti A. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch. Dermatol. Res. 283:1991;230-232.
7. Delgado M., Ganea D. Vasoactive intestinal peptide a type 2 cytokine. J. Immunol. 166:2001;2907-2912.
8. Berth-Jones J. Six area six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br. J. Dermatol. 135:1996;25-30.
9. Nilsson S.F.E., Maepea O. Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat. Acta Physiol. Scand. 129:1987;17-26.
10. Lowman M.A., Benyon R.C., Church M.K. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br. J. Pharmacol. 95:1988;121-130.
11. Lotti T., Hautmann G., Panconesi E. Neuropeptides in skin. J. Am. Acad. Dermatol. 33:1995;482-496.
12. Kakurai M., Fujita N., Murata S., Furukawa Y., Demitsu T., Nakagawa H. Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors. J. Invest. Dermatol. 116:2001;743-749.
13. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93:1999;126-138.
14. Iwakabe K., Shimada M., Ohta A., Yahata T., Ohmi Y., Habu S., Nishimura T. The restraint stress drives a shift in Th1/Th2 balance toward Th2-dominant immunity in mice. Immunology. 62:1998;39-43.